Arthritis Monoclonal Antibodies Market Forecast Reveals Where Future Industry Value Will Be Created
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Arthritis Monoclonal Antibodies Market Value Expansion And Long-Term Growth Outlook
The arthritis monoclonal antibodies sector has undergone significant expansion in the past few years. Projections indicate an increase from $66.45 billion in 2025 to $71.66 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. Several factors have fueled this historic growth, including a rising incidence of rheumatoid arthritis, the limited efficacy of traditional disease-modifying antirheumatic drugs (DMARDs), heightened awareness of biologic treatment options, the broadening of rheumatology services within hospital settings, and greater overall healthcare investment.
The arthritis monoclonal antibodies market is projected to experience significant expansion over the coming years, reaching a value of $98.46 billion by 2030 with a compound annual growth rate (CAGR) of 8.3%. This forecast period growth is driven by the advancement of next-generation monoclonal antibodies, the growing availability of biosimilars, the rise of personalized immunotherapy approaches, an expanding elderly demographic affected by arthritis conditions, and enhanced reimbursement frameworks for biologic therapies. Key trends shaping this period include a heightened uptake of biologic therapies for autoimmune arthritis, a growing inclination toward targeted monoclonal antibody treatments, the emergence of early and aggressive treatment strategies, the proliferation of biosimilars for arthritis-related monoclonal antibodies, and better patient access facilitated by hospitals and specialty clinics.
Download A Free Sample Report For Comprehensive Market Insights:
Arthritis Monoclonal Antibodies Market Expansion Drivers: What Is Shaping Future Growth?
The increasing number of approvals for personalized medicines is anticipated to drive growth in the arthritis monoclonal antibody market moving forward. Personalized medicines are defined as therapeutic products or treatments specifically customized to meet individual patient needs. These therapies are developed based on a patient’s genetic, biomarker, phenotypic, or psychosocial characteristics, which help predict how they will respond to a particular treatment. Monoclonal antibodies (mABs) represent the latest generation of drugs that align with the personalized medicine framework, offering the potential to enhance patient outcomes and improve healthcare efficiency. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization dedicated to advancing personalized medicine, released a report highlighting the significance of 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 notable new or expanded indications for 12 diagnostic testing products. Consequently, the rising rate of approvals for personalized medicines is fueling the expansion of the arthritis monoclonal antibody market.
Arthritis Monoclonal Antibodies Market Segment Landscape And Growth Potential
The arthritis monoclonal antibodies market covered in this report is segmented –
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hospitals, Research Institutes, Other End-Users
Arthritis Monoclonal Antibodies Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Leading players in the arthritis monoclonal antibody space are increasingly introducing new biosimilar products like Hulio to offer more cost-effective treatment options. Designed as a biosimilar to AbbVie’s highly successful rheumatoid arthritis drug Humira, Hulio provides an alternative for patients. For example, in July 2023, Biocon Biologics—a biosimilar-focused subsidiary of Biocon Limited based in India—rolled out Hulio (adalimumab-fkjp), which mirrors Humira’s composition. This monoclonal antibody, prescribed for ailments such as rheumatoid arthritis and psoriatic arthritis, is available at a cost 5% less than Humira, currently priced at $6,922 per carton.
Arthritis Monoclonal Antibodies Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the arthritis monoclonal antibodies market are Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.
Access The Complete Arthritis Monoclonal Antibodies Market Report:
Arthritis Monoclonal Antibodies Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the arthritis monoclonal antibodies market in 2025. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
